uniQure N.V. (QURE) shares tumbled 36.58 percent to $9.91, down $5.72 on Monday, after the company reported a full-year net loss and disclosed FDA feedback indicating that current Phase 1/2 data for AMT-130 in Huntington's disease are insufficient to support a marketing application.
The stock is currently trading at $9.91, compared with a previous close of $15.63. It opened at $9.19 and has traded between $8.96 and $10.28 during the session on the Nasdaq. Trading volume stands at 8.53 million shares, well above its average volume of 2.64 million shares.
For full year 2025, revenue declined to $16.1 million from $27.1 million in 2024. Net loss narrowed to $199.0 million, or $3.46 per share, from $239.6 million, or $4.92 per share, a year earlier. The stock has traded in a 52-week range of $7.76 to $71.50.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.